- Activity of tafasitamab in combination with rituximab in subtypes of aggressive lymphoma2023 | First Faculty of Medicine
- Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- ABCL-022 Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab +- Lenalidomide + R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell LymphomaPublication without faculty affiliation
- Treatment of nonHodgkin lymphoma with monoclonal antibodies in 20192019 | Faculty of Medicine in Hradec Králové
- Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options2022 | First Faculty of Medicine